
Mibor 3.5 Injection
Marketer
Celon Laboratories Ltd
Salt Composition
Bortezomib (3.5mg)
Overview Mibor 3.5 Injection
Bortezomib 3.5mg injection treats multiple myeloma and mantle cell lymphoma by inhibiting cancer cell proliferation. Administered intravenously by a healthcare professional, the dosage and frequency are determined by your physician based on your condition and may vary. Strict adherence to the prescribed regimen is crucial; incorrect usage or overdose can lead to severe adverse effects. Therapeutic benefits may take weeks or months to manifest; discontinue only under medical supervision. Common side effects include tiredness, nausea, vomiting, and anorexia. Increased fluid intake is often recommended. Operating machinery or driving should be avoided due to potential drowsiness and dizziness. This medication can reduce blood cell counts (red and white), increasing infection risk, necessitating regular blood tests monitoring blood cell levels, along with cardiac, hepatic, and uric acid levels. Prior to treatment, disclose any liver, kidney, heart conditions, or bleeding disorders to your doctor. Report cognitive symptoms like memory impairment or difficulty concentrating. Inform your healthcare provider of all medications you are taking, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding; effective contraception is essential for both partners throughout treatment.
Uses of Mibor 3.5 Injection
Myeloma and mantle cell lymphoma
Major Benefits of Mibor 3.5 Injection:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
Common Side effects of Mibor 3.5 Injection:
- Low blood platelets
- Fatigue
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Psychiatric disturbances
- Nausea
- Vomiting
- Loss of appetite
- Fever
- Anemia (low number of red blood cells)
- Diarrhea
- Decreased appetite
- Decreased white blood cell count (neutrophils)
- Constipation
How to use Mibor 3.5 Injection:
Administering this medication will be done by your healthcare provider. Self-medication is strictly prohibited.
How Mibor 3.5 Injection works:
Mibor 3.5 Injection is an anticancer agent that inhibits the cellular degradation of proteins. This protein accumulation within cancer cells ultimately triggers their demise.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent use of Mibor 3.5 Injection and alcohol may result in pronounced somnolence.
PregnancyCONSULT YOUR DOCTOR
Administering Mibor 3.5 Injection during pregnancy is contraindicated due to established risks to fetal development. In exceptional, life-threatening circumstances, a physician might consider its use if the potential benefits outweigh the known hazards. Physician consultation is essential.
Breast feedingUNSAFE
Administering Mibor 3.5 Injection while breastfeeding is contraindicated due to the potential for infant toxicity. Evidence indicates a risk of harm to the nursing infant.
DrivingUNSAFE
Administering Mibor 3.5 Injection may result in adverse reactions that impair driving capabilities. These reactions can include fatigue, vertigo, syncope, or visual disturbances, potentially affecting driving safety.
KidneyCAUTION
Individuals with advanced kidney impairment should exercise caution when using Mibor 3.5 Injection. Dosage modification of Mibor 3.5 Injection might be necessary. Physician consultation is recommended.
LiverCAUTION
Exercise caution when administering Mibor 3.5 Injection to individuals with hepatic impairment; dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Mibor 3.5 Injection :
Omitting a scheduled dose of Mibor 3.5 Injection warrants immediate physician consultation.
Facts to Know About Mibor 3.5 Injection
| Label | Value |
|---|---|
| Chemical Type | Phenylalanine-Based Compounds |
| Developing Habits | No. |
| Treatment Category | Cancer Drugs |
